Earnings call transcript: Acarix Q1 2026 shows strong U.S. growth By Investing.com

Acarix reported Q1 2026 revenue of SEK 2.4 million, up 40% year over year, with U.S. revenue rising 63% y/y and 90% on a constant-currency basis. Gross margin held at 81%, operating costs fell 32% quarter over quarter, and net loss improved 38%, while management expects Saudi/GCC approvals in Q3 2026 and analysts forecast 169% revenue growth for FY2026. The stock rose 0.19%, suggesting a constructive but cautious market reaction.

Analysis

Acarix is signaling an inflection less from headline growth than from mix and operating leverage: U.S. unit placements, patch pull-through, and reimbursement progress are starting to stack into a more durable recurring revenue model. The important second-order effect is that every incremental installed system increases the probability of repeat patch consumption and payer validation, so the business can re-rate before it ever reaches profitability if utilization stays on track. That makes the next two quarters more about conversion of installed base into recurring economics than about absolute top-line size.

The cleanest read-through is to CMS-adjacent reimbursement names and small-cap medtech peers: if Acarix keeps winning local payer decisions and moves closer to a CPT pathway, it reduces perceived friction for broader diagnostic reimbursement in outpatient chest-pain triage. Conversely, any delay in the U.S. government’s procurement cadence or MENA approvals creates a valuation air pocket because the stock’s current momentum is anchored to a narrow set of catalysts. FX also matters more than the market may be pricing; with revenue still small, translation noise can overwhelm the underlying operating improvement and create misleading quarter-to-quarter volatility.

The contrarian case is that consensus may be over-anchoring on percentage growth while underestimating how much commercial acceleration is needed to absorb fixed costs and finance expansion. At this scale, a few lost orders or delayed payer decisions can swamp the quarter, so the stock can gap violently on seemingly minor execution misses. The real catalyst window is 3-9 months: if reimbursement milestones and primary-care adoption continue, the market may start discounting a break-even path well before GAAP profitability is visible.

For portfolio construction, this is a better catalyst trade than a long-duration fundamental compounder. The setup favors trading around confirmed reimbursement/regulatory updates rather than holding through long quiet periods, because volatility will be event-driven and asymmetric to the downside on delay.

Key Decisions for Investors

• Long ACARIX into the next reimbursement/regulatory headline window (4-12 weeks) via a starter position only; target a 2-3x upside on a successful payer or KSA update, but size small because single-name liquidity risk is high.
• Use call spreads rather than outright equity in ACARIX for the next 3-6 months; the thesis is event convexity, and options cap downside if U.S. procurement or MENA timing slips.
• If you want the same theme with lower idiosyncratic risk, pair long a U.S. healthcare reimbursement beneficiary basket against short a broad small-cap medtech basket for 1-2 quarters; the relative winner should be names with clearer payer visibility.
• Take profits aggressively on ACARIX strength into catalyst realization; if the stock rerates before profitability evidence, the multiple can compress quickly on any operational miss.
• Do not chase on FX-adjusted revenue print alone; wait for confirmation in installed-base conversion and recurring patch growth over the next two quarters before adding size.